Finished 2022 with Q4 sales orders of USD 2.7M representing a 3.3X increase over Q4 2021 Sales orders growth for 2023 is projected to be 3X...
Dr. Garibaldi’s 40 years of experience brings industry-leading pharmaceuticals development expertise to the Scientific Board of Advisors. His appointment demonstrates the company’s resolve to leverage its...
Vancouver, British Columbia, and Rehovot, Israel–(Newsfile Corp. – January 11, 2023) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB:CNVCF) (“BioHarvest” or “the Company”) invites its shareholders and the...
Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – December 29, 2022) – BioHarvest Sciences Inc.(“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF) is pleased to provide...
Cash flow break-even projected for Q4 2023 Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – December 15, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest”...
This collaboration ensures first-of-their-kind consistent cannabinoid compositions for 575 DEA-licensed cannabis medical research institutions developing cures for PTSD, pain management, anxiety conditions and more Vancouver, British...
This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction. Vancouver, British Columbia and Rehovot, Israel–(Newsfile...
Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – November 14, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or “the Company”) announces...
BioHarvest demonstrates unprecedented Cannabinoids tuning and elicitation capabilities (12X increase versus original plant) using its proprietary Bio-Plant CELLicitation™ platform technology Contains high amounts of minor Cannabinoids...
Vancouver, British Columbia, and Rehovot, Israel–(Newsfile Corp. – October 13, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or the “Company”) is...